U.S. Biopharmaceutical CMO & CRO Market (2023 - 2030) Size, Share & Trends Analysis Report By Source (Mammalian, Non-mammalian), By Service (Contract Manufacturing, Contract Research), By Product (Biologics, Biosimilars), And Segment Forecasts

Market Segmentation

U.S. Biopharmaceutical CMO & CRO Source Outlook (Revenue, USD Million, 2018 - 2030)
- Mammalian
- Non-mammalian
U.S. Biopharmaceutical CMO & CRO Service Type Outlook (Revenue, USD Million, 2018 - 2030)
- Contract Manufacturing
  - Process Development
    - Downstream
    - Upstream
  - Fill & Finish Operations
  - Analytical & QC studies
  - Packaging
- Contract Research
  - Oncology
  - Inflammation & Immunology
  - Cardiology
  - Neuroscience
  - Others
U.S. Biopharmaceutical CMO & CRO Product Outlook (Revenue, USD Million, 2018 - 2030)
- Biologics
  - Monoclonal antibodies (MAbs)
  - Recombinant Proteins
  - Vaccines
  - Antisense, RNAi, & Molecular Therapy
  - Others
- Biosimilars

Report content

Qualitative Analysis

Industry overview
Industry trends
Market drivers and restraints
Market size
Growth prospects
Porter’s analysis
PESTEL analysis
Key market opportunities prioritized
Competitive landscape
- Company overview
- Financial performance
- Product benchmarking
- Latest strategic developments